← Browse by Condition
Medical Condition
primary mediastinal large b cell lymphoma pmbcl
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 1, Phase 2
NCT06208735 Phase 1
Recruiting
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Enrollment
24 pts
Location
Canada
Sponsor
British Columbia Cancer Agency
NCT06014762 Phase 1
Recruiting
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Enrollment
120 pts
Location
United States
Sponsor
Poseida Therapeutics, Inc.
NCT07473167 Phase 1, Phase 2
Recruiting
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Enrollment
98 pts
Location
South Korea
Sponsor
TICAROS Co., Ltd.
NCT06544265 Phase 1
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
Enrollment
18 pts
Location
United States
Sponsor
Verismo Therapeutics